Ethical considerations in testing workers for the -Glu69 marker of genetic susceptibility to chronic beryllium disease

Journal of Occupational and Environmental Medicine

Volumn 48, Issue 4, 2006, Pages 434-443

  Silver, Ken ^a   Sharp, Richard R ^b  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DP ANTIGEN; HLA DPB1; HLA-DPB1;

ARTICLE; BERYLLIOSIS; EMPLOYER; ETHICS; GENETIC SUSCEPTIBILITY; HUMAN; PREDICTION AND FORECASTING; PROFESSIONAL SECRECY; SAFETY; SCREENING; WORKER; CONFIDENTIALITY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; METHODOLOGY; OCCUPATIONAL MEDICINE; REVIEW; RISK ASSESSMENT; VOLUNTARY PROGRAM;

BERYLLIOSIS; CONFIDENTIALITY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HLA-DP ANTIGENS; HUMANS; OCCUPATIONAL MEDICINE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; VOLUNTARY PROGRAMS;

EID: 33646828347     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000200878.16077.3b     Document Type: Article

References (93)

1. Dillard P. Community occupational health clinics in the free market. In: Levenstein C, Wooding J, eds. Work, Health and Environment: Old Problems, New Solutions. New York: Guilford; 1997:387-404.
2. Nelkin D. Ethical conflicts in occupational medicine. In: Nelkin D, ed. The Language of Risk: Conflicting Perspectives on Occupational Health. Beverly Hills, CA: Sage Publications; 1985.
3. Samuels SW. On the ethical practice of environmental and occupational medicine. In: Rom WN, ed. Environmental and Occupational Medicine. Philadelphia: Lippincott-Raven Publishers; 1998:1795-1805.
4. Walsh DC. Corporate Physicians: Between Medicine and Management. New Haven, CT: Yale University Press; 1987:267.
5. Andrews LB, Jaeger AS. Confidentiality of genetic information in the workplace. Am J Law Med 1991;27:75-108.
6. Draper E. Risky Business: Genetic Testing and Exclusionary Practices in the Hazardous Workplace. Cambridge: Cambridge University Press; 1991:315.
7. Murray TH. Genetic testing at work: how should it be used? Technol Rev. 1985:50-59.
8. Omenn GS. Predictive identification of hypersusceptible individuals. J Occup Med. 1982;24:369-374.
9. Rothstein MA. Employee selection based on susceptibility to occupational illness. Michigan Law Rev. 1983;81:1378-1496.
10. Rubenstein D. Burlington Northern Railroad Discovers a Third Rail., Corporate Legal Times. July 2001:68.
11. U.S. Equal Employment Opportunity Commission. EEOC's Memorandum in Support of Petition for a Preliminary Injunction. 2001, unpublished: United States District Court, Northern District of Iowa, Western Division. p. 22.
12. U.S. Equal Employment Opportunity Commission. EEOC's Petition for Preliminary Injunction, in Equal Opportunity Commission v. Burlington Northern Santa Fe Railroad Company, n.d., unpublished: United States District Court, Northern District of Iowa, Western Division. p. 7.
13. Schulte PA, Lomax G. Assessment of the scientific basis for genetic testing of railroad workers with carpal tunnel syndrome. J Occup Environ Med. 2003;45:592-600.
14. Stockton DW, Meade RA, Netscher DT, et al. Hereditary neuropathy with liability to pressure palsies is not a major cause of idiopathic carpal tunnel syndrome. Arch Neurol. 2001;58:1635-1637.
15. Silverstein M. Analysis of medical screening and surveillance in 21 Occupational Safety and Health Administration standards: support for a generic medical surveillance standard. Am J Ind Med. 1994;26:283-295.
16. Himmelstein J, Andersson JGB. Low back pain: risk evaluation and preplacement screening. Occup Med. 1988;3:255-269.
17. Duster T. Backdoor to Eugenics. New York: Routledge; 1990.
18. LaMontagne AD, Christiani, DC Kelsey KT. Utility of the complete blood count in routine medical surveillance for ethylene oxide exposure. Am J Ind Med. 1993;24:191-206.
19. Rothstein MA. Genetics and the work force of the next hundred years. Columbia Business Law Rev. 2000;371:371-402.
20. U.S. General Accounting Office. U.S. Locations Where Beryllium Was Used or Detected. Washington, DC: U.S. General Accounting Office; 2001.
21. Henneberger PK, Goe SK, Miller WE, Doney B, Groce DW. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. J Occup Environ Hygiene. 2004;1:648-659.
22. Newman LS, Maier LA, Martyny JW, Mroz MM, VanDyke M, Sackett HM. Beryllium workers' health risks. J Occup Environ Hygiene. 2005;2:D48-D50.
23. Welch L, Ringen K, Bingham E, et al. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med. 2004;46:207-218.
24. Hilmas DE. Contract no. DE-AC05-00OR22750: fourth quarter FY2003 report. Memorandum to White E. Oak Ridge Institute for Science and Education (ORISE), former beryllium workers medical surveillance program (BMSP). Oak Ridge, TN: ORISE; 2003.
25. Newman LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect. 1996;104:953-956.
26. Brancaleone P, Weynand B, De Vuyst P, Stanescu D, Pieters T. Lung granulomatosis in a dental technician. Am J Ind Med. 1998;34:628-631.
27. Kotloff RM, Richman PS, Greenacre JK, Rossman MD. Chronic beryllium disease in a dental laboratory technician. Am Rev Respir Dis. 1993;147:205-207.
28. Rom WN, Lockey JE, Lee JS, et al. Pneumoconiosis and exposures of dental laboratory technicians. Am J Public Health. 1984;74:1252-1257.
29. Mroz MM, Beryllium. In: Bingham E, Cohrssen B, Powell CH. Patty's Toxicology. New York: John Wiley & Sons, Inc.; 2001:177-220.
30. Cullen MR, Kominsky JR, Rossman MD, et al. Chronic beryllium disease in a precious metal refinery: clinical epidemiologic and immunologic evidence for continuing risk from exposure to low level beryllium fume. Am Rev Respir Dis. 1987;135:201-208.
31. 3. Am J Ind Med. 1996;30:16-25.
32. Martyny JW, Hoover MD, Mroz MM, et al. Aerosols generated during beryllium machining. J Occup Environ Med. 2000;42:8-18.
33. Yoshida T, Shima S, Nagaoka K, et al. A study on the beryllium lymphocyte transformation tests and the beryllium levels in working environment. Ind Health. 1997;35:374-379.
34. Wambach PF, Tuggle RM. Development of an eight-hour occupational exposure limit for beryllium. Appl Occup Environ Hygiene. 2000;15:581-587.
35. U.S. Department of Energy. Chronic beryllium disease prevention program; final rule. Fed Regis. 1999;64:68854-68914.
36. Sawyer RT, Maier LA, Kittle LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol. 2002;2:249-261.
37. Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect. 1996;104(S5):937-943.
38. Kreiss K, Mroz MM, Zhen BB, Martyny JW, Newman LS. Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis. 1993;148:985-991.
39. Maier LA, Newman LS. Beryllium disease. In: Rom WN, ed. Environmental and Occupational Medicine. Philadelphia: Lippincott-Raven Publishers; 1998:1021-1035.
40. Jonmaire P, Beryllium. In: Harbison RD, ed. Hamilton and Hardy's Industrial Toxicology. Mosby: St. Louis; 1998:37-41.
41. Saltini C, Amicosante M. Beryllium disease. Am J Med Sci. 2001;321:89-98.
42. Williams WJ. Beryllium disease. In: Parkes WR, ed. Occupational Lung Disorders. Oxford: Butterworth-Heinemann Ltd; 1994:571-592.
43. Maier LA, Raynolds MV, Young DA, Barker EA, Newman LS. Angiotensin-1 converting enzyme polymorphisms in chronic beryllium disease. Am J Respir Crit Care Med. 1999;159:1342-1350.
44. Maier LA, Sawyer RT, Bauer RA, et al. High beryllium-stimulated TNF-alpha is associated with the -308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease. Am J Respir Crit Care Med. 2001;164:1192-1199.
45. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease. Science. 1993;262:242-244.
46. Wang Z, White PS, Petrovic M, et al. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J Immunol. 1999;163:1647-1653.
47. Saltini C, Richeldi L, Losi M, et al. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur Respir J. 2001;18:677-684.
48. Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni B, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am J Ind Med. 1997;32:337-340.
49. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen class II amino acid epitopes. Am Rev Respir Crit Care Med. 2002;165:788-794.
50. Wang Z, Farris GM, Newman LS, et al. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology. 2001;165:27-38.
51. Maier LA, McGrath DS, Sato H, et al. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003;171:6910-6918.
52. Newman LS. To Be2+ or not to Be2+: immunogenetics and occupational exposure. Science. 1993;262:197-198.
53. Scott BL, Wang Z, Marrone BL, Sauer NN. Potential binding modes of beryllium with the class II major histocompatibility complex HLA-DP: a combined theoretical and structural database study. J Inorganic Biochem. 2003;94:5-13.
54. Weston A, Ensey J, Kreiss K, Keshava C, McCanlies E. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med. 2002;41:457-465.
55. GeneLetter. Case: beryllium to test or not to test. GeneSage, Inc.; 1996.
56. Lomax GP. Evaluating Genetic Testing for Susceptibility to Occupationally-Induced Disease: A Case Study of Chronic Beryllium Disease. Doctoral Dissertation. Berkeley, CA: University of California, Berkeley; 2002:144.
57. DOE/LANL. In: Nicholas R, ed. Beryllium Worker Safety: A Training in Six Modules [video]. LANL: Los Alamos, NM; 2001.
58. Anon. New tests will help predict, diagnose chronic beryllium disease, Dateline Los Alamos. April 2000. p. 1-4.
59. Taylor GM, Dearden S, Ravetto P, et al. Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet. 2002;11:1585-1597.
60. White MT. Genetic susceptibility research in occupational disease: should subjects have access to interim findings? J Occup Environ Med. 2000;42:246-250.
61. McCanlies EC, Kreiss K, Andrew M, Weston A. HLA-DPB1 and chronic beryllium disease: a HuGE review. Am J Epidemiol. 2003;157:388-398.
62. Tesh SN. Hidden Arguments: Political Ideology and Disease Prevention Policy. New Brunswick, NJ: Rutgers University Press; 1988:215.
63. Galen RS, Gambino SR. Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses. New York: Wiley; 1975:237.
64. Davenport K. A safe house for toxic metal. Santa Fe New Mexican. 2000, p. A1.
65. Office of Inspector General, Audit Report: Beryllium Oxide Operations at the Y-12 National Security Complex. Washington, DC: U.S. Department of Energy; 2003.
66. Snodgrass R. New beryllium facility aims for utmost safety. Los Alamos Monitor, 2000, 1-2.
67. Center for Occupational and Environmental Health, University of California at Berkeley., Informing workers about genetic test results; 2002. Available at: http://coeh.berkeley.edu/Research/policy/ policy.htm. Accessed December 20, 2005.
68. Froines, JR. An Automated System for Task-Based Evaluation of Size Distributions of Beryllium Aerosol at the Los Alamos Beryllium Technology Facility. Annual Report. Irvine, CA: University of California Toxic Substances Research & Teaching Program, 1998-1999; 1998:19.
69. Stefaniak AB, Hoover MD, Dickerson RM, et al. Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease. AIHA J. 2003;64:297-305.
70. University of California Research Partnership Initiative. An Automated System for Task-Based Evaluation of Size Distributions of Beryllium Aerosol at the Los Alamos Beryllium Technology Facility. Los Alamos: Los Alamos National Laboratory; 2003.
71. Kreiss K, Beryllium Disease. In: Levy BS, ed. Preventing Occupational Disease and Injury. Washington, DC: American Public Health Association; 2005:120-6.
72. Secretary's Advisory Committee on Genetic Testing, Enhancing the Oversight of Genetic Tests. Recommendations of the SACGT. Bethesda, MD: National Institutes of Health: Bethesda; 2002:32.
73. Rothstein MA. Legal concerns in worker notification and the use of biomarkers in medical surveillance. In: Mendelsohn ML, Peeters JP, Normandy MJ, eds. Biomarkers in Occupational Health: Progress and Perspectives. Washington, DC: Joseph Henry Press; 1995:37-47.
74. Rothstein MA. Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic Era. New Haven, CT: Yale University Press; 1997.
75. Bingham E. Ethical issues of genetic testing for workers. In: Mendelsohn ML, Mohr LC, Peeters JP, eds. Biomarkers: Medical and Workplace Applications. Washington, DC: Joseph Henry Press; 1998:415-422.
76. Rose SL, Pietri CE. Workers as research subjects: a vulnerable population. J Occup Environ Med. 2002;44:401-405.
77. Oversight Hearings on Office of Federal Contract Compliance Programs. In: Subcommittee on Employment Opportunities of the Committee on Education and Labor. Washington, DC: U.S. Government Printing Office; 1987:102-105.
78. Guillen RR. "Scientific Colonialism": Scientific Practice and Chicana/o Identity in an American Southwest Technopole, Doctoral Dissertation. Department of History. Los Angeles: University of California at Los Angeles; 2004:394.
79. Department of Energy Employee Compensation Plan. In: Committee on Health, Education, Labor, and Pensions. Columbus, OH: U.S. Government Printing Office; 2000:76.
80. Compensation for Illnesses Realized by Department of Energy Workers Due to Exposure to Hazardous Materials, in Subcommittee on Immigration and Claims, Committee on the Judiciary. Washington, DC: Government Printing Office; 2000.
81. Egilman DS, Bagley S, Biklen M, Golub AS, Bohme SR. The beryllium "double standard" standard. Int J Health Services. 2003;33:769-812.
82. Egilman D, Bagley S, Connolly S. Anything but beryllium: the beryllium industry's corruption of safety information [letter]. Am J Ind Med. 2002;42:270-271.
83. Public Meeting with Assistant Secretary of Energy Dr. David Michaels. October 30, 1999: Piketon, Ohio. Available at: http://www.eh.doe.gov/advocacy/ meetings/ openmeetings.html; accessed December 20, 2005.
84. Public Meeting with Dr. David Michaels, DOE Assistant Secretary of Energy for Environment, Safety & Health. December 8, 1999: Oak Ridge, TN. Available at: http://www.eh.doe.gov/advocacy/ meetings/openmeetings.html. Accessed December 20, 2005.
85. Public Meeting. February 3, 2000: Richland, Washington. Available at: http:// www.eh.doe.gov/advocacy/meetings/ openmeetings.html. Accessed December 20, 2005.
86. Public Meeting with Dr. David Michaels, Assistant Secretary of Environmental Health and Safety. February 25, 2000: Las Vegas, Nevada. Available at: http:// www.eh.doe.gov/advocacy/meetings/ openmeetings.html. Accessed December 20, 2005.
87. Meeting on the Energy Employees Occupational Illness Compensation Program, Senator Jeff Bingaman, Congressman Tom Udall, Assistant Energy Secretary Bev Cook. May 11, 2002: Espanola, NM. p. 73.
88. Moreno JD. Convenient and captive populations. In: Kahn JP, Mastroianni AC, Sugarman J, eds. Beyond Consent: Seeking Justice in Research. New York: Oxford University Press; 1998:111-129.
89. Welsome E. The Plutonium Files: American's Secret Medical Experiments in the Cold War. New York: Dial Press; 1999:580.
90. Subcommittee on Oversight and Investigations of the Committee on Commerce. In: Whistleblowers at Department of Energy Facilities: Is There Really "Zero Tolerance" for Contractor Retaliation. Washington, DC: Government Printing Office; 2000.
91. Carpenter T. Statement before the Subcommittee on Oversight and Investigations. In: Whistleblowers at Department of Energy Facilities: Is There Really "Zero Tolerance" for Contractor Retaliation. Washington, DC: Government Printing Office; 2000.
92. Nicas M, Lomax GP. A cost-benefit analysis of genetic screening for susceptibility to occupational toxicants. J Occup Environ Med. 1999;41:535-544.
93. Samuels SW. An alternative understanding of aggression in the work environment. Eur J Oncol. 2000;5:55-61.